A genetic health panel analyzes specific genes to find variants that may increase your chance of developing certain conditions. It provides insight into risk for these conditions, not a diagnosis.

People with a strong family history of related conditions or known genetic disorders should consult their healthcare provider or a genetic counselor to determine the most appropriate testing.

Additionally, the test is not appropriate for patients who have had a bone marrow or stem cell transplant, have had a blood transfusion in the last two weeks, have had a liver transplant or are currently being treated for cancer.

You must confirm that you have not had a bone marrow or stem cell transplant, a blood transfusion in the last two weeks, a liver transplant, are not currently being treated for cancer and that you are not considered high risk for the conditions being tested.

This test does not diagnose disease, assess your current health status, or detect all genetic variants. It should not be used alone to make medical decisions. Other factors such as environmental and lifestyle risk factors may affect the risk of developing a disease.

This test provides genetic risk information based on specific genetic variants. It does not detect all variants related to a given disease. Not finding a variant does not rule out other genetic variants that may be related to the disease. Genetic research is ongoing, and the amount of available evidence may vary across populations.

This test is not a substitute for visits to a doctor or other qualified healthcare professional. It does not diagnose disease. You should consult your healthcare provider if you have questions or concerns about your health.

Your results will be delivered through the Labcorp Patient Portal. You will also be notified when your results are ready and a personal video explaining your results will be shared with you.

While not all cancers are hereditary, about 5–10% are linked to inherited genetic variants passed down through families.^1,2
 

Among hereditary cancers, some of the most identified include hereditary breast and ovarian cancer (often associated with BRCA1 and BRCA2 genes) and Lynch syndrome, which is the most common inherited cause of colorectal cancer.^3,4
 

This test looks at many of the most well-studied genes associated with hereditary cancer risk, including those linked to breast, ovarian, colorectal, and several other cancers. However, it does not assess every possible variant associated with cancer and not all hereditary risks are fully understood.

If a genetic variant is identified, it may indicate an increased risk, but it does not mean you will necessarily develop cancer. A genetic counselor can help interpret your results in the context of your personal and family history and guide the next steps.

Cancer risk varies from person to person and is affected by genetic, lifestyle, and environmental factors. You may be at higher risk if you^5,6:

• Have a personal or family history of cancer, especially at younger ages
• Use tobacco or are exposed to secondhand smoke
• Have certain lifestyle factors, such as obesity, physical inactivity, or alcohol use
• Have been exposed to infections (e.g., HPV) or environmental carcinogens
• Are older, as cancer risk increases with age

Individuals with inherited genetic variants linked to cancer may have a higher risk compared to the general population. Understanding both genetic and non-genetic risk factors can help guide personalized screening and prevention strategies.

In the United States, a federal law called the Genetic Information Nondiscrimination Act (GINA) protects you.

Under GINA:

• Health insurance companies cannot use your genetic test results to change your coverage, eligibility, or costs
• Employers (with 15 or more employees) cannot use your genetic information when making decisions about hiring, firing, or job assignments

However, certain types of insurance may use genetic information when making coverage or pricing decisions, which vary by state. These types of insurance include:

• Life insurance
• Disability insurance
• Long-term care insurance

To learn more:

• Visit www.ginahelp.org for information about GINA and its protections
• Visit the National Human Genome Research Institute website for details about laws in your state

Cardiovascular disease (CVD), including heart disease, stroke, heart failure, and arrythmias, is the leading cause of death in the United States, responsible for approximately 1 in 3 deaths.⁷
 

Risk for cardiovascular disease is influenced by both genetic and lifestyle factors. Common risk factors include⁷:

• High blood pressure, high cholesterol, and smoking
• Diabetes, obesity, and physical inactivity
• Family history of heart disease, which may indicate inherited risk

Some individuals may carry inherited genetic variants associated with conditions such as familial hypercholesterolemia, cardiomyopathies, or arrhythmias, which can significantly increase risk. Identifying risks early may support proactive monitoring and prevention.

Genetic test results are based on your DNA. The same genes are analyzed for every person, regardless of race or ethnicity.

However, your genetic ancestry may affect the way certain results are interpreted. Some genetic variants are better studied in certain populations than others. As a result, in some cases:

1. There may be more or less information available about a specific genetic variant
2. Some results may be classified as a variant of uncertain significance (VUS), meaning there is not yet enough evidence to determine its impact on health

As genetic research continues to expand, our understanding is expected to improve over time.

If you have questions about your results, a genetic counselor can help interpret your findings in the context of your personal and family history.

This comprehensive genetic risk panel evaluates 163 genes associated with inherited conditions. While many conditions are represented, some of the key conditions include:
 

• Cancer Risk – such as breast, colorectal and ovarian cancers.

• Cardiovascular & Cardiac Conditions – Many genes are associated with inherited cardiomyopathies, arrhythmias, aortic disease, and familial hypercholesterolemia — the leading cause of sudden cardiac death in working-age adults.

• Hereditary Metabolism & Iron Disorders – conditions that are often missed but highly manageable once identified.

• Connective Tissue & Vascular Disease – conditions such as Marfan syndrome and vascular Ehlers-Danlos that can cause catastrophic events in otherwise healthy-seeming individuals.

• Pharmacogenomic-Adjacent Risk – such as clotting risk, for people on certain medications.
   

Because many genes are linked to multiple conditions, we recommend discussing your results with a genetic counselor for personalized interpretation.
 

The Marker by Labcorp Genetic Health Panel tests for each gene listed below, along with conditions it may be associated with:
 

• ABCD1 – X-linked adrenoleukodystrophy

• ACTA2 – Aortopathy

• ACTC1 – Cardiomyopathy, congenital heart disease, skeletal condition

• ACTN2 – Cardiomyopathy, neuromuscular condition

• ACVRL1 – Hereditary hemorrhagic telangiectasia, pulmonary arterial hypertension

• APC – Gastrointestinal, endocrine, nervous system/brain cancer, and sarcoma

• APOB – Familial hypercholesterolemia, familial hypobetalipoproteinemia

• ATM – Breast, gynecologic, gastrointestinal, and prostate cancer

• ATP7B – Wilson disease

• AXIN2 – Gastrointestinal cancer

• BAG3 – Cardiomyopathy, neuromuscular condition

• BAP1 – Renal/urinary tract and skin cancer

• BARD1 – Breast cancer

• BMPR1A – Gastrointestinal cancer

• BMPR2 – Pulmonary arterial hypertension

• BRCA1 – Breast, gynecologic, gastrointestinal, and prostate cancer

• BRCA2 – Breast, gynecologic, gastrointestinal, prostate, and skin cancer

• BRIP1 – Gynecologic cancer

• BTD – Biotinidase deficiency

• CACNA1C – Arrhythmia, Timothy syndrome

• CACNA1S – Malignant hyperthermia susceptibility, neuromuscular conditions

• CALM1 – Arrhythmia

• CALM2 – Arrhythmia

• CALM3 – Arrhythmia

• CASQ2 – Arrhythmia

• CAV1 – Pulmonary arterial hypertension, lipodystrophy

• CAV3 – Neuromuscular condition

• CDC73 – Endocrine and renal/urinary tract cancer

• CDH1 – Breast and gastrointestinal cancer, blepharocheilodontic syndrome

• CDK4 – Skin cancer

• CDKN1B – Endocrine and gastrointestinal cancer

• CDKN2A – Skin, gastrointestinal, and nervous system/brain cancer

• CHEK2 – Breast, endocrine, and prostate cancer

• COL3A1 – Aortopathy

• COL5A1 – Connective tissue disorder

• COL5A2 – Connective tissue disorder

• CRYAB – Cataracts, neuromuscular condition

• CSRP3 – Cardiomyopathy

• DES – Arrhythmia, cardiomyopathy, neuromuscular condition

• DICER1 – Endocrine, gynecologic, lung, nervous system/brain, renal/urinary tract cancer, and sarcoma

• DMD – Cardiomyopathy, neuromuscular condition

• DSC2 – Arrhythmia, cardiomyopathy

• DSG2 – Arrhythmia, cardiomyopathy

• DSP – Arrhythmia, cardiomyopathy

• EGFR – Lung cancer

• EMD – Neuromuscular condition

• ENG – Hereditary hemorrhagic telangiectasia

• EPCAM – Gastrointestinal, gynecologic, renal/urinary tract, nervous system/brain, prostate, and skin cancer

• F11 – Bleeding condition

• F2 – Bleeding condition

• F5 – Bleeding condition

• F9 – Bleeding condition

• FBN1 – Marfan syndrome, lipodystrophy, connective tissue disorder, skeletal conditions

• FH – Renal/urinary tract, endocrine, nervous system/brain cancer, and sarcoma

• FHL1 – Cardiomyopathy, neuromuscular condition

• FLCN – Renal/urinary tract cancer

• FLNC – Arrhythmia, cardiomyopathy, neuromuscular conditions

• G6PD – Glucose-6-phosphate dehydrogenase deficiency

• GAA – Glycogen storage disease

• GCH1 – Neuromuscular condition

• GDF2 – Hereditary hemorrhagic telangiectasia, pulmonary arterial hypertension

• GLA – Fabry disease

• GREM1 – Gastrointestinal cancer

• HAMP – Hereditary hemochromatosis

• HCN4 – Arrhythmia, cardiomyopathy, aortopathy

• HFE – Hereditary hemochromatosis

• HJV – Hereditary hemochromatosis

• HMBS – Acute intermittent porphyria

• HNF1A – Maturity-onset diabetes of the young

• HNF1B – Renal cysts and diabetes syndrome

• HOXB13 – Prostate cancer

• JUP – Arrhythmia, cardiomyopathy

• KCNE1 – Arrhythmia

• KCNH2 – Arrhythmia

• KCNJ2 – Arrhythmia, Andersen-Tawil syndrome

• KCNQ1 – Arrhythmia

• KIT – Gastrointestinal cancer and sarcoma, immune condition, skin condition

• LAMP2 – Danon disease

• LDLR – Familial hypercholesterolemia

• LDLRAP1 – Familial hypercholesterolemia

• LMNA – Arrhythmia, cardiomyopathy, neuromuscular conditions, progeria, lipodystrophy, and others

• LZTR1 – Nervous system/brain cancer, Noonan spectrum disorders

• MAX – Endocrine and nervous system/brain cancer, polydactyly-macrocephaly syndrome

• MEFV – Familial Mediterranean fever

• MEN1 – Endocrine, gastrointestinal, and nervous system/brain cancer, endocrine condition

• MET – Renal/urinary tract cancer, skeletal condition

• MITF – Skin cancer, Waardenburg syndrome

• MLH1 – Gastrointestinal, gynecologic, renal/urinary tract, nervous system/brain, prostate, and skin cancer

• MSH2 – Gastrointestinal, gynecologic, renal/urinary tract, nervous system/brain, prostate, and skin cancer

• MSH3 – Gastrointestinal cancer

• MSH6 – Gastrointestinal, gynecologic, renal/urinary tract, nervous system/brain, prostate, and skin cancer

• MUTYH – Gastrointestinal cancer

• MYBPC3 – Cardiomyopathy

• MYH11 – Aortopathy

• MYH7 – Cardiomyopathy, neuromuscular condition

• MYL2 – Cardiomyopathy

• MYL3 – Cardiomyopathy

• MYLK – Aortopathy

• NF1 – Breast, endocrine, gastrointestinal, nervous system/brain cancer, and sarcoma

• NF2 – Nervous system/brain cancer

• NTHL1 – Gastrointestinal cancer

• OTC – Ornithine transcarbamylase deficiency

• PALB2 – Breast, gynecologic, gastrointestinal, and prostate cancer

• PCSK9 – Familial hypercholesterolemia

• PDGFRA – Gastrointestinal cancer and sarcoma

• PKP2 – Arrhythmia, cardiomyopathy

• PLN – Arrhythmia, cardiomyopathy

• PMS2 – Gastrointestinal, gynecologic, renal/urinary tract, nervous system/brain, prostate, and skin cancer

• POLD1 – Gastrointestinal cancer and MDPL syndrome

• POLE – Gastrointestinal cancer

• POT1 – Skin and nervous system/brain cancer, and sarcoma

• PRKAG2 – Arrhythmia, cardiomyopathy

• PRKAR1A – Endocrine, nervous system/brain cancer, and sarcoma, acrodysostosis

• PRKG1 – Aortopathy

• PROC – Hereditary thrombophilia

• PROS1 – Hereditary thrombophilia

• PTCH1 – Skin, nervous system/brain cancer, and sarcoma

• PTEN – Breast, gynecologic, gastrointestinal, endocrine, renal/urinary tract, nervous system/brain, and skin cancer

• RAD51C – Breast and gynecologic cancer

• RAD51D – Breast and gynecologic cancer

• RB1 – Retinoblastoma, skin cancer, and sarcoma

• RBM20 – Arrhythmia, cardiomyopathy

• RET – Endocrine and nervous system/brain cancer, gastrointestinal condition

• RPE65 – Retinal dystrophy

• RYR1 – Malignant hyperthermia susceptibility, neuromuscular conditions

• RYR2 – Arrhythmia, cardiomyopathy

• SCN5A – Arrhythmia, cardiomyopathy

• SDHA – Endocrine, nervous system/brain, and gastrointestinal cancer, sarcoma, mitochondrial disorder

• SDHAF2 – Endocrine and nervous system/brain cancer

• SDHB – Endocrine, nervous system/brain, renal/urinary tract, and gastrointestinal cancer, sarcoma

• SDHC – Endocrine, nervous system/brain, renal/urinary tract, and gastrointestinal cancer, sarcoma

• SDHD – Endocrine, nervous system/brain, and gastrointestinal cancer, sarcoma

• SERPINA1 – Alpha-1 antitrypsin deficiency

• SERPINC1 – Hereditary thrombophilia

• SGCD – Neuromuscular condition

• SLC40A1 – Hereditary hemochromatosis

• SMAD3 – Aortopathy

• SMAD4 – Gastrointestinal cancer, hereditary hemorrhagic telangiectasia, aortopathy, Myhre syndrome

• SMAD9 – Pulmonary arterial hypertension

• SMARCA4 – Gynecologic, nervous system/brain, and renal/urinary tract cancer, Coffin-Siris syndrome

• SMARCB1 – Nervous system/brain and renal/urinary tract cancer, Coffin-Siris syndrome

• STK11 – Breast, gynecologic, gastrointestinal, lung, and testicular cancer

• TCAP – Cardiomyopathy

• TFR2 – Hereditary hemochromatosis

• TGFB2 – Aortopathy, skeletal condition

• TGFB3 – Aortopathy

• TGFBR1 – Aortopathy, skin tumors

• TGFBR2 – Aortopathy

• TMEM127 – Endocrine and nervous system/brain cancer

• TMEM43 – Arrhythmia, cardiomyopathy

• TNNC1 – Cardiomyopathy

• TNNI3 – Cardiomyopathy

• TNNT2 – Cardiomyopathy

• TP53 – Breast, gynecologic, gastrointestinal, endocrine, nervous system/brain, renal/urinary tract, prostate, skin, and hematologic cancer, sarcoma

• TPM1 – Cardiomyopathy

• TRDN – Arrhythmia

• TSC1 – Endocrine, gastrointestinal, renal/urinary tract, and nervous system/brain cancer

• TSC2 – Endocrine, gastrointestinal, renal/urinary tract, and nervous system/brain cancer

• TTN – Cardiomyopathy, neuromuscular condition

• TTR – Hereditary transthyretin-mediated amyloidosis

• VCL – Cardiomyopathy

• VHL – Endocrine, gastrointestinal, renal/urinary tract, and nervous system/brain cancer

• WT1 – Renal/urinary tract cancer

Your testing will be performed in a CLIA-certified clinical laboratory. Labcorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. Our labs perform regular quality assurance testing to ensure our results are accurate.

Your results will be provided to you through our secure online portal to view or print. Results are also made available through a secure portal to the independent healthcare provider who placed your test order.  If you are accessing your results through your Labcorp Patient™ account, all users linked to the account will have access to all OnDemand test results. Results may also be provided to a local, state, and/or federal health authority; for example, many states require the testing laboratory and physician to report test results for certain communicable diseases, such as COVID-19, to local or state health departments.  

If you have questions or comments regarding the Labcorp Notice of Privacy Practices, or have a complaint about our use or disclosure of your PHI or our privacy practices, please contact: privacyofficer@labcorp.com, call us at (877) 234-4722 (877-23-HIPAA) and ask for the Labcorp HIPAA Privacy Officer, or send a written request to: HIPAA Privacy Officer, Labcorp, 531 South Spring Street, Burlington, NC 27215. You also may file a complaint with the Secretary of the U.S. Department of Health and Human Services.

Visit the Labcorp OnDemand® website to browse and purchase laboratory tests and create your Labcorp Patient™ account to view your results. All Labcorp OnDemand testing requires an order from an authorized healthcare professional. For your convenience, Labcorp OnDemand has contracted with independent professional entities (collectively, Providers) to deliver healthcare provider services. Visit a Labcorp location for sample collection; or, if using an at-home collection kit, collect your sample yourself. We’ll let you know when your results are ready and can be accessed through your Labcorp Patient™ account.

To align with clinical best practices, we’ve set an age maximum of 100 for consumer-initiated testing. This limit was set to encourage individuals in more advanced age groups - who may have complex medical needs - to receive personalized guidance about testing from their healthcare providers.